Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.04 +1.0%	$1.26	$0.86 ▼ $3.78	$227.48M	0.35	4.39 million shs	7.89 million shs
ELVN Enliven Therapeutics	$19.99 +5.8%	$20.76	$13.30 ▼ $30.03	$980.89M	0.93	368,293 shs	359,926 shs
IMNM Immunome	$10.01 +1.0%	$9.57	$5.15 ▼ $16.73	$871.27M	1.93	1.02 million shs	982,833 shs
URGN Urogen Pharma	$20.11 +4.7%	$14.61	$3.42 ▼ $21.01	$930.37M	1.12	1.58 million shs	1.22 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-8.04%	-19.53%	+8.10%	-56.36%
ELVN Enliven Therapeutics	+4.31%	-1.72%	-15.86%	-5.03%	-11.40%
IMNM Immunome	+2.59%	-8.66%	+14.70%	+24.34%	-21.60%
URGN Urogen Pharma	+5.26%	-7.34%	+34.83%	+94.53%	+32.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.5191 of 5 stars	3.4	2.0	0.0	2.4	2.5	0.6
ELVN Enliven Therapeutics	2.6578 of 5 stars	3.5	2.0	0.0	2.0	4.2	0.0
IMNM Immunome	1.7079 of 5 stars	3.5	0.0	0.0	2.5	2.5	0.0
URGN Urogen Pharma	4.6382 of 5 stars	4.5	4.0	4.5	2.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	708.08% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	111.97% Upside
IMNM Immunome	3.00	Buy	$23.14	127.56% Upside
URGN Urogen Pharma	3.00	Buy	$31.43	62.37% Upside

Current Analyst Ratings Breakdown

Latest ALLO, IMNM, ELVN, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	11,428.64	N/A	N/A	$2.01 per share	0.52
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
IMNM Immunome	$9.04M	97.92	N/A	N/A	$3.09 per share	3.29
URGN Urogen Pharma	$91.87M	9.75	N/A	N/A	($2.02) per share	-9.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/13/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	N/A
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	N/A
URGN Urogen Pharma	-$126.87M	-$3.32	N/A	N/A	N/A	-164.44%	-97,487.15%	-59.38%	N/A

Latest ALLO, IMNM, ELVN, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.82	-$1.05	-$0.23	-$1.05	$23.06 million	$24.22 million
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
ELVN Enliven Therapeutics	N/A	21.07	21.06
IMNM Immunome	N/A	12.13	12.13
URGN Urogen Pharma	N/A	4.14	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ELVN Enliven Therapeutics	95.08%
IMNM Immunome	44.58%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
ELVN Enliven Therapeutics	25.90%
IMNM Immunome	7.69%
URGN Urogen Pharma	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
IMNM Immunome	40	87.04 million	80.35 million	Optionable
URGN Urogen Pharma	200	46.26 million	44.09 million	Optionable

ALLO, IMNM, ELVN, and URGN Headlines

Recent News About These Companies

17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners Ltd

August 13 at 7:06 AM | marketbeat.com

UroGen Pharma’s Earnings Call: Achievements and Challenges

August 13 at 2:04 AM | msn.com

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Buy" from Brokerages

August 13 at 2:29 AM | americanbankingnews.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript

August 12 at 4:03 PM | msn.com

HC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock Price

August 12 at 8:22 AM | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPS

August 11 at 2:33 PM | marketbeat.com

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

August 10 at 2:34 PM | finance.yahoo.com

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% on Disappointing Earnings

August 9, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak Earnings

August 8, 2025 | marketbeat.com

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...

August 8, 2025 | finance.yahoo.com

UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI

August 8, 2025 | tipranks.com

UroGen (URGN) Q2 Revenue Rises 11%

August 7, 2025 | aol.comA

UroGen (URGN) Q2 Revenue Rises 11%

August 7, 2025 | aol.comA

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7, 2025 | investing.com

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7, 2025 | investing.com

Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft

August 7, 2025 | tipranks.com

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

UroGen Pharma Q2 2025 Earnings Preview

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALLO, IMNM, ELVN, and URGN Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.04 +0.01 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.03 (+3.37%)

As of 04:21 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Enliven Therapeutics NASDAQ:ELVN

$19.99 +1.10 (+5.82%)

Closing price 04:00 PM Eastern

Extended Trading

$20.00 +0.01 (+0.05%)

As of 04:20 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Immunome NASDAQ:IMNM

$10.01 +0.10 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$10.02 +0.01 (+0.05%)

As of 04:10 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Urogen Pharma NASDAQ:URGN

$20.11 +0.91 (+4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$20.10 0.00 (-0.02%)

As of 04:15 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time